Invitrogen

GLIS2 Polyclonal Antibody

7 Published Figures

View all (3) GLIS2 antibodies

Questions & Answers

Questions & Answers

Antibody Testing Data (2)
Published Figures (7)

GLIS2 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

GLIS2 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

FIGURE: 1 / 9

GLIS2 Antibody (PA5-72849) in IHC (P)

Immunohistochemistry of GLIS2 in mouse kidney tissue with GLIS2 Polyclonal Antibody (Product # PA5-72849) at 5 µg/mL.

GLIS2 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

GLIS2 Antibody in Western Blot (WB)

GLIS2 Antibody in Immunocytochemistry (ICC/IF)

GLIS2 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

GLIS2 Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P))

GLIS2 Antibody in Western Blot (WB)

GLIS2 Antibody in Western Blot (WB)

GLIS2 Antibody in Western Blot (WB)

GLIS2 Antibody in Western Blot (WB)

Product Image Gallery

GLIS2 Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Immunohistochemistry of GLIS2 in mouse kidney tissue with GLIS2 Polyclonal Antibody (Product # PA5-72849) at 5 µg/mL.

GLIS2 Antibody in Western Blot (WB) — Western Blot analysis of GLIS2 in K562 cell lysate with GLIS2 Polyclonal Antibody (Product # PA5-72849) at 1 µg/mL.

GLIS2 Antibody in Immunocytochemistry (ICC/IF) — Constructed GLIS2 knockout cell line in HSC lines. ( A ) Lentiviral knockout vector mapping for mouse GLIS2. Gene knockout in the vector is based on CRISPR/Cas9, and Cas9 expression is controlled by the Tet-On system. ( B ) The T7E1 assay was used to detect the effect of 3 sgRNAs targeting the mouse GLIS2, with sgRNA-2 having the best knockout effect. ( C ) GLIS2 deficiency cell lines were created by multiplying single cells. ( D , E ) Genomic PCR and qRT-PCR were used to detect viral elements integrated into the genomes of different cell lines (n = 3, SD; * P < .05; ** P < .01; *** P < .001). ( F , G ) GLIS2 knockout was confirmed using qRT-PCR and Western blot. Dox+ denotes the addition of doxycycline in cell culture, Dox- denotes the absence of doxycycline, and Dox+/- denotes the addition of doxycycline for culture followed by the removal of doxycycline for continuous culture. (n = 3, SD; * P < .05; ** P < .01; *** P < .001). ( H ) GLIS2 immunofluorescence staining in a GLIS2-SG cell. GLIS2 is green; DAPI is blue. NC, negative control

GLIS2 Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Figure 1 GLIS2 is downregulated in fibrosis liver tissue. ( A ) H&E, Masson, and immunohistochemistry (IHC) were used to examine histological changes and the immunoreactivity of GLIS2 in liver samples from patients with varying degrees of hepatic fibrosis (HF). ( B ) GLIS2 (red) was found in liver samples from patients with varying degrees of HF using immunofluorescence. DAPI was used to visualize the nucleus. ( C ) H&E, Masson, and Sirius red staining were used to examine histological changes in liver tissues in model and control mice. ( D ) Enzyme-linked immunosorbent assay was used to detect serum levels of total bilirubin, ALT, and AST in model and control mice (n = 5, SD; * P < .05; ** P < .01; *** P < .001). ( E , F ) The mRNA and protein expression levels of fibrosis-related indices (alpha-SMA, Col1alpha1, TIMP1) and GLIS2 were determined in model and control mice using qRT-PCR and Western blot (n = 3, SD; * P < .05; ** P < .01; *** P < .001). ( G ) Immunofluorescence detected GLIS2 (red) in mouse liver tissues. DAPI was used to visualize the nucleus. ( H ) Mice were used to isolate primary mouse hepatocytes (left) and primary HSCs (right). ( I , J ) qRT-PCR and Western blot were used to detect GLIS2 mRNA and protein expression levels in mouse primary HSCs and liver tissues (n = 5, SD; * P < .05; ** P < .01; *** P < .001). GPT, glutamic-pyruvic transaminase.

GLIS2 Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P)) — Glis2 suppresses hepatic fibrogenesis in vivo. a Representative pictures of immunofluorescence in mouse liver tissues with fibrosis identified by Masson's staining: GFP (green), Glis2 (red). b Relative protein expression of Glis2, GFP and GFAP proteins detected in mouse liver tissues in each group through western blotting. c Serum levels of hydroxyproline, TB, ALT, and AST detected using biochemical kits. d Contents of IL-1beta, IL-8, TNF-alpha, and CCL-2 in liver tissues detected by ELISAs. Relative mRNA and protein levels of Glis2, GFAP, p75NTR, desmin, and alpha-SMA in mouse liver tissues determined by qRT-PCR ( e ) and western blotting ( f ). g Immunoreactivity of Glis2, alpha-SMA, p75NTR, and desmin in mouse liver tissues assessed by immunohistochemistry. h Immunofluorescence of GFAP (green) and Glis2 (red) in JS-1 cells with or without Glis2 overexpression. Mean + SD; ANOVA for ( b - f ); * P < 0.05; ** P < 0.01; *** P < 0.001.

GLIS2 Antibody in Western Blot (WB) — Fig. 7 MALAT1 represses Glis2 expression by recruiting DNMT1. a Relative expression levels of lncRNAs in fibrotic liver tissues determined by qRT-PCR ( n = 6). Relative mRNA levels of MALAT1 in mouse liver tissues ( b ) and HSCs ( c ) determined by qRT-PCR. d The direct interaction between MALAT1 and DNMT1 verified by RIP-qPCR in human liver tissues, mouse liver tissues and JS-1 cells. e Subcellular colocalization of MALAT1 and DNMT1 observed by FISH in combination with IF. Red, DNMT1; green, MALAT1; blue, DAPI. f The direct interaction between MALAT1 and DNMT1 determined in human liver tissues, mouse liver tissues and JS-1 cells via the RNA pulldown assay. g , h Relative mRNA and protein levels of Glis2 measured by qRT-PCR and western blotting, respectively. Mean + SD; Student's t test for ( a - d , f ), and ANOVA for ( g , h ); * P < 0.05; ** P < 0.01; *** P < 0.001.

GLIS2 Antibody in Western Blot (WB) — Fig. 5 DNMT1 mediates Glis2 promoter methylation. a The location of the CpG island on the Glis2 promoter. b The methylation status of Glis2 in fibrotic liver tissues of patients detected through bisulfite sequencing. c The interaction between the Glis2 promoter and DNMT1, DNMT3a, and DNMT3b detected via the ChIP-qPCR assay in mouse liver tissues. d Methylation status of the Glis2 promoter in quiescent and activated HSCs. e The interaction between the Glis2 promoter and DNMT1 detected via the ChIP-qPCR assay. f , g The mRNA and protein levels of Glis2 in HSCs measured by qRT-PCR and western blotting, respectively. Mean + SD for ( b - e ); ANOVA for ( f , g ); * P < 0.05;** P < 0.01; *** P < 0.001.

GLIS2 Antibody in Western Blot (WB) — Glis2 inhibits the activation of HSCs in vitro. a Bright-field and fluorescence detection of Glis2-overexpressing JS-1 cells. b , c The mRNA and protein levels of Glis2 in JS-1 cells determined by qRT-PCR and western blotting, respectively. d Cell proliferation monitored using the CCK-8 assay. e Cell proliferation was assessed using the EdU incorporation assay. f Cell migration detected via the Transwell migration assay. g , h Relative Glis2, GFAP, p75NTR, desmin, and alpha-SMA mRNA and protein levels in HSCs measured by qRT-PCR and western blotting, respectively. Mean + SD; Student's t test for ( b ) and ( c ); ANOVA for ( d , f - h ); * P < 0.05;** P < 0.01; *** P < 0.001.

GLIS2 Antibody in Western Blot (WB) — Overexpression of GLIS2 ensures the acetylation level of PPAR-gamma and alleviates liver fibrosis in mice. ( A ) PPAR-gamma acetylation was detected in HSCs from hepatic fibrosis mice induced by CCL4. ( B ) DNA pulldown assay identified PPAR-gamma that binds to the CD36 promoter in HSCs from mice with hepatic fibrosis induced by CCL4. ( C ) AAV-GLIS2 virus vector map. The short GFAP promotor controls mGLIS2 expression in the vector. ( D , E ) GLIS2 overexpression was confirmed in hepatocytes and HSCs using qRT-PCR and Western blot, respectively (n = 5, SD; * P < .05; ** P < .01; *** P < .001). ( F ) PPAR-gamma acetylation levels were detected in HSCs from AAV-NC mice and AAC-GLIS2 mice. ( G ) In AAV-NC mice and AAC-GLIS2 mice, a DNA pulldown assay detected PPAR-gamma that binds to the CD36 promoter in HSCs. ( H , I ) The mRNA and protein expression levels of fibrosis-related genes (alpha-SMA, Col1alpha1, TIMP1) in liver tissues of AAV-NC mice and AAC-GLIS2 mice were determined by qRT-PCR and Western blot, respectively (n = 3, SD; * P < .05; ** P < .01; *** P < .001). ( J ) Total bilirubin, ALT, and AST serum levels were measured using enzyme-linked immunosorbent assay in AAV-NC and AAC-GLIS2 mice (n = 5, SD; * P < .05; ** P < .01; *** P < .001). ( K ) H&E, Masson, and Sirius red staining were used to examine histological changes in liver tissues in AAV-NC mice and AAC-GLIS2 mice, respectively.

Product Details

PA5-72849

Applications

Tested Dilution

Publications

Western Blot (WB)

1-2 µg/mL

View 2 publications 2 publications

Immunohistochemistry (Paraffin) (IHC (P))

5 µg/mL

View 2 publications 2 publications

Immunocytochemistry (ICC/IF)

-

View 1 publication 1 publication

ELISA (ELISA)

Assay-Dependent

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Published species

Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

GLIS2 antibody for an 18 amino acid peptide near the center of human GLIS2. The immunogen is within amino acids 260 - 310 of GLIS2.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS

Contains

0.02% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Ambient (domestic); Wet ice (international)

AB_2718703

Target Information

Members of the Kruppel-like zinc finger protein family, such as GLIS2, function as activators and/or repressors of gene transcription.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Transcriptional regulation of Glis2 in hepatic fibrosis.

Experimental & molecular medicine

Gong HY,Zhou PC,Zhang HY,Chen LM,Zhou YM,Liu ZG

Published figure using GLIS2 polyclonal antibody (Product # PA5-72849) in Western Blot

Sat Jul 01 00:00:00 UTC 2023

Transcriptional regulation of Glis2 in hepatic fibrosis.

Experimental & molecular medicine

Gong HY,Zhou PC,Zhang HY,Chen LM,Zhou YM,Liu ZG

Published figure using GLIS2 polyclonal antibody (Product # PA5-72849) in Western Blot

Sat Jul 01 00:00:00 UTC 2023

GLIS2 Prevents Hepatic Fibrosis by Competitively Binding HDAC3 to Inhibit Hepatic Stellate Cell Activation.

Cellular and molecular gastroenterology and hepatology

Zhang H,Zhou P,Xing W,Chen L,Zhou Y,Yang H,Fu K,Liu Z

PA5-72849 was used in ELISA, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to conclude that GLIS2 deficiency promotes myofibroblastic transdifferentiation and activation of hepatic stellate cells (HSCs).

Fri Jan 27 00:00:00 UTC 2023

GLIS2 Prevents Hepatic Fibrosis by Competitively Binding HDAC3 to Inhibit Hepatic Stellate Cell Activation.

Cellular and molecular gastroenterology and hepatology

Zhang H,Zhou P,Xing W,Chen L,Zhou Y,Yang H,Fu K,Liu Z

PA5-72849 was used in ELISA, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to conclude that GLIS2 deficiency promotes myofibroblastic transdifferentiation and activation of hepatic stellate cells (HSCs).

Fri Jan 27 00:00:00 UTC 2023

GLIS2 Prevents Hepatic Fibrosis by Competitively Binding HDAC3 to Inhibit Hepatic Stellate Cell Activation.

Cellular and molecular gastroenterology and hepatology

Zhang H,Zhou P,Xing W,Chen L,Zhou Y,Yang H,Fu K,Liu Z

PA5-72849 was used in ELISA, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to conclude that GLIS2 deficiency promotes myofibroblastic transdifferentiation and activation of hepatic stellate cells (HSCs).

Fri Jan 27 00:00:00 UTC 2023

GLIS2 Prevents Hepatic Fibrosis by Competitively Binding HDAC3 to Inhibit Hepatic Stellate Cell Activation.

Cellular and molecular gastroenterology and hepatology

Zhang H,Zhou P,Xing W,Chen L,Zhou Y,Yang H,Fu K,Liu Z

PA5-72849 was used in ELISA, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to conclude that GLIS2 deficiency promotes myofibroblastic transdifferentiation and activation of hepatic stellate cells (HSCs).

Fri Jan 27 00:00:00 UTC 2023

GLIS2 Prevents Hepatic Fibrosis by Competitively Binding HDAC3 to Inhibit Hepatic Stellate Cell Activation.

Cellular and molecular gastroenterology and hepatology

Zhang H,Zhou P,Xing W,Chen L,Zhou Y,Yang H,Fu K,Liu Z

PA5-72849 was used in ELISA, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to conclude that GLIS2 deficiency promotes myofibroblastic transdifferentiation and activation of hepatic stellate cells (HSCs).

Fri Jan 27 00:00:00 UTC 2023

Bioinformatics

Protein Aliases: GLI-Kruppel family member GLI5; GLI-similar 2; Kruppel-like factor 16 (neuronal); Kruppel-like zinc finger protein GLIS2; nephrocystin-7; Neuronal Krueppel-like protein; Zinc finger protein GLI5; Zinc finger protein GLIS2

View more View less

Gene Aliases: Gli5; GLIS2; Klf16; NKL; NPHP7

View more View less

UniProt ID: (Human) Q9BZE0, (Mouse) Q8VDL9

View more View less

Entrez Gene ID: (Human) 84662, (Mouse) 83396, (Rat) 302946

View more View less

transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding protein binding transcription regulatory region DNA binding metal ion binding nucleic acid binding DNA binding transcription factor activity, sequence-specific DNA binding

negative regulation of transcription from RNA polymerase II promoter transcription, DNA-templated regulation of transcription, DNA-templated regulation of transcription from RNA polymerase II promoter transcription from RNA polymerase II promoter multicellular organism development nervous system development cell differentiation negative regulation of sequence-specific DNA binding transcription factor activity negative regulation of smoothened signaling pathway negative regulation of transcription, DNA-templated positive regulation of transcription, DNA-templated positive regulation of transcription from RNA polymerase II promoter

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

We're here to help

Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.

Contact tech support